In a statement to Insider, Novo Nordisk, the company that makes Wegovy and Ozempic, said that Gila monsters and the discovery of exendin-4 "did not have anything to do with our decision to develop long-acting GLP-1 receptor agonists" for obesity, because "that was based on GLP-1 biology in humans." But the company also said that "the GLP-1-like effect of exendin-4" in Gila monsters was "an important contribution to the field," as it led to the development of the very first injectable drug of its kind
Violeta Iotova MD, PhD, DSc, Head of Department of Paediatrics, Medical UniversityVarna, for her expertise and assistance in completing this manuscript
Forest plot with P-score for biological and anthropometric outcomes
Sciatic nerve regeneration appears after transection with BPC 157 application, local (into the tube), intragastric or intraperitoneal